Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arecor Ltd.
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who is in the spotlight this year.
Sarah Howell, one of In Vivo’s 2021 Rising Leaders, was appointed CEO of Arecor in 2015 and has led the company’s transformation into a successful clinical-stage biotechnology company. In an exclusive interview, Howell described Arecor as focused on “affordable innovation,” particularly in disease areas with large and growing patient populations, such as diabetes.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
- Drug Discovery Tools